Slide 1: Vaishali Pharma Limited Result Update Presentation
Vaishali Pharma Limited Result Update Presentation May 2018
Slide 2: Disclaimer
Click to edit Master title style Disclaimer This presentation has been prepared by Vaishali Pharma Limited (the “Company”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be r
Slide 3: Table of Contents
Click to Table of edit Master title style Contents Director’s Message & Financial Highlights Company Overview Industry Overview Business Overview Way Ahead 3
Slide 4: Director's Message & Financial Highlights
Director’s Message & Financial Highlights
Slide 5: Director's Message
Click to edit Director’s Master title style Message Commenting on the results, Ms. Priyanka Vasani – Chief Operating Officer, Vaishali Pharma Limited said : “This second half and full financial year end 2017-18, our Company has reported a growth with fantastic H2 FY18 sales of Rs. 45 Cr, an increase
Slide 6: Half Yearly Profit & Loss Highlights
ClickYearly Half to edit Master Profit & Loss title style Highlights Rs. Crs H2 FY18 H1 FY18 Sequential % Change Revenue 45.03 22.89 96.7% Revenue growth is on Cost of goods sold 40.27 19.63 account of entry into newer markets and Employee Cost 1.04 1.00 addition of new Other Cost 1.60 1.39 produc
Slide 7: Annual Financial Highlights
Click toFinancial Annual edit Master title style Highlights Total Income (Rs. Crore) EBITDA (Rs. Crore) 67.92 3.47 66.71 2.99 63.97 0.55 FY16 FY17 FY18 FY16 FY17 FY18 PAT (Rs. Crore) 0.80 0.71 -0.04 FY16 FY17 FY18 Financials as per IND AS Guidelines 7
Slide 8: Annual Profit & Loss Highlights
Click toProfit Annual edit&Master title style Loss Highlights Rs. Crs FY18 FY17 FY16 Revenue 67.92 63.92 66.71 Cost of goods sold 59.90 56.14 62.03 Revenue increase by 6% on year on year basis on Employee Cost 2.04 1.59 1.56 account of addition of Other Cost 3.00 2.77 2.57 value added products EBI
Slide 9: Balance Sheet Highlights
Click toSheet Balance edit Highlights- Master title style As on 31st Mar’17 As on 31st As on 31st As on 31st As on 31st Rs. Crs Rs. Crs Mar-18 Mar-17 Mar-18 Mar-17 Non-current assets 5.27 4.96 Shareholder’s Funds 20.60 3.98 Property , Plant & Equipment 0.98 1.14 Share capital 6.59 3.00 Intangible As
Slide 10: Company Overview
Click to edit Master title style Company Overview
Slide 11: Company Overview
Click to edit Company Master title style Overview Among fastest growing companies in pharmaceutical industry across globe Established in 1989 Incorporated as Private limited company in 2008 Diversified Product Portfolio Present dosage forms comprises of: Tablet, Capsule, Liquid Oral, Injection
Slide 12: Journey So Far
Click to edit Journey Master title style So Far Ventured into Export of Received new Product formulations. VPPL Team registrations in Myanmar has set a new benchmark - and Kenya Designed Biggest milestone for Started business achieving Rs. 120 Cr Sales Organizational Vaishali Pharma’s Sale
Slide 13: Experienced Management Team
Click to edit Master Experienced title style Management Team Mr. Atul Vasani Chairman & Managing Director Over 29 years of experience in pharmaceutical industry A phenomenal personality with strong business acumen. Ethical & perseverant approach towards business and focused visionary personnel
Slide 14: Industry Overview
Click to edit Master title style Industry Overview
Slide 15: Global Pharmaceutical Market - An Overview
Click toPharmaceutical Global edit Master titleMarket- style An Overview Value of global prescription drug market - $816bn in 2016, representing growth of 4.9% US market - 5.6% to $320bn in 2016, from $303bn in 2015 Pfizer - #1 ranked Company both globally and in US with market share of 5.6% and 6.8
Slide 16: Indian Pharma Export Market
Click toPharma Indian edit Master Exporttitle style Market Indian pharma companies capitalising on export opportunities in regulated and semi-regulated markets In FY16, India exported pharmaceutical products worth $16.89 billion, with number expected to reach $40 billion by 2020 Department of
Slide 17: Indian Pharma Market Size
Click toPharma Indian edit Master Markettitle style Size Rapidly growing Healthcare sector Indian healthcare sector, one of fastest Leading Pharma producer growing sectors, expected to advance at a Indian pharmaceutical sector accounts for CAGR of 17% to reach $250 billion over about 2.4% of glo
Slide 18: Indian Pharma Sector Revenue
Click toPharma Indian edit Master Sectortitle style Revenue Indian pharmaceuticals market witnessed growth at CAGR of 17.90%, during 2005-16, with market increasing from $6 billion in 2005 to Revenue of Indian pharmaceutical sector $36.7 billion in 2016 (USD billion) 60 By 2020, India - likely t
Slide 19: Healthcare Sector Trends
Click to editSector Healthcare Master title style Trends Strong growth in healthcare expenditure: Healthcare industry - growing at tremendous pace owing to its strengthening coverage, services and increasing expenditure by public as well private players Till 2020, market expected to record a CAG
Slide 20: Business Overview
Click to edit Master title style Business Overview
Slide 21: Business Structure
Click to edit Business Master title style Structure Vaishali Pharma Ltd. (Business Activities) Import of Domestic Export APIs Manufacturing Manufacturing & Manufacturing & & Export of Export of Active Contract Supply of Active Manufacturing & Export of Export of Herbal & Pharmaceutical Manufacturing
Slide 22: Business Model
Click to edit Business Master title style Model Exclusive Branding Import & Export Domestic Sales Joint Ventures Outsourcing Strategic Alliance Contract Manufacturing 22
Slide 23: Strong & Diverse Product Portfolio
Click Strongto & edit Master Diverse title style Product Portfolio... Domestic International Excipients Formulations Herbal Active Pharmaceutical Surgical Veterinary Ingredients (APIs) 23
Slide 24: Key Strengths
ClickStrengths Key to edit Master title style ISO 9001 : 2008 for quality management Offering range from Formulations, Bulk from BM Trada UKAS Drugs, APIs, Veterinary Products, Surgical ISO 9001 : 2015 from Deutsche Quality Assurance Accreditation Board, Germany and Neutraceutical Products M
Slide 25: Creating Strong Global Presence
Click to edit Creating Master Strong title Global style Presence Export contributed 24% of Total Revenue in FY18 Presence across over 15 countries 25
Slide 26: Global Certifications
Click toCertifications Global edit Master title style Company Certifications Star Export House ISC- Global NSIC- CRISIL NSE - EMERGE Formulation Certifications Myanmar Tajikistan Nicaragua Zimbabwe Kenya DR Congo Surgical Certifications Conformite’ Europe’ene ISO 9001 : 2015 26
Slide 27: Way Ahead
MEDICAL Health Care Dovtor Hospital Pharmacist Nore Dentist FirotAd Surgeon Emergency
Slide 28: Way Ahead
ClickAhead Way to edit Master title style Increased Global Presence Currently have presence in Asian, African, CIS and Latin American Countries Revenue from export increased from Rs. 0.52 Crs in FY 2012 – 13, Rs. 1.84 Crs in FY 2013-14, Rs. 0.92 Crs in FY 2014-15, Rs. 8.90 Crs in FY 2015-16 Rs.
Slide 29: Thank You
Click to edit Master Thank You title style VAISHALI VAISHALI IN VAISHALI.BO For further information, please contact: Company : Investor Relations Advisors : Vaishali Pharma Limited Bridge Investor Relations Pvt. Ltd. Ms. Priyanka Vasani Ms Savli Mangle Chief Operating Officer org@vaishalipharma.com